Modern Management of Hepatic Metastatic Disease

Research output: Chapter in Book/Report/Conference proceedingChapter


Colorectal cancer is the third leading cause of cancer deaths in both men and women with 136,830 new cases in the United States estimated to be diagnosed in 2014 [1]. For individuals diagnosed with colorectal cancer, approximately 20% of patients will have metastatic disease at the time of initial diagnosis [2]. Despite the overall incidence of colorectal cancer declining, the number of patients presenting with metastases has remained relatively unchanged. In multiple population-based studies, the incidence of synchronous liver metastases was reported to be 14–18% [3–5]. Similarly, on a population level, the rate of metachronous liver metastases was approximately 12–14% at 3 years [3, 4]. The liver is the most common site of distant colorectal metastases and disease is limited to this site in at least one-third of the patients [6]. Overall, approximately 50% of patients will develop liver metastases at some point during the course of their disease.

Original languageEnglish (US)
Title of host publicationComprehensive Rectal Cancer Care
PublisherSpringer International Publishing
Number of pages32
ISBN (Electronic)9783319989020
ISBN (Print)9783319989013
StatePublished - Jan 1 2019

Bibliographical note

Publisher Copyright:
© Springer Nature Switzerland AG 2019.


Dive into the research topics of 'Modern Management of Hepatic Metastatic Disease'. Together they form a unique fingerprint.

Cite this